October 22, 2001
AmeriPath Estimates Third Quarter Earnings
FOR IMMEDIATE RELEASE
Contact: Gregory A. Marsh Michelle D. Getty Vice President & CFO
Investor Relations AmeriPath, Inc. AmeriPath, Inc. 561-712-6211
561-712-6260 E-mail: gmarsh@ameripath.com E-mail: invrel@ameripath.com
AMERIPATH ESTIMATES THIRD QUARTER EARNINGS OF $.34
PER SHARE EXCEEDING ANALYST CONSENSUS EARNINGS OF $.33
PER SHARE
Riviera Beach, FL, October 22, 2001 - AmeriPath, Inc.
(Nasdaq:PATH), one of the nation's leading providers
of anatomic pathology services, today announced that
it expects third quarter earnings to be $.34 per share,
exceeding the consensus of the analysts which follow
the Company by $.01.
The Company plans to release its complete financial
results for the third quarter and nine months ended September
30, 2001 on Tuesday, October 30, 2001, before the market
opens. The Company will broadcast its full third quarter
financial results conference call on Tuesday, October
30, 2001, at 10:00 a.m. Eastern Time over the Internet.
The call will by hosted by James C. New, Chairman and
Chief Executive Officer, and Gregory A. Marsh, Vice President
and Chief Financial Officer. All stockholders and investors
are encouraged to participate. This event is available
by visiting the Investor Relations page on Company's
website located at http://www.ameripath.com, or through
CCBN's Street Events website, located at http://www.streetevents.com.
Listeners should go to one of these websites at least
fifteen minutes before the call to register and to download
and install any necessary audio software. For those unable
to attend the live webcast, a replay will be available
on these websites for the next 60 days. There is no charge
to access the event. A replay of the call will also be
available by telephone beginning at 12:00 p.m., October
30 to 12:00 p.m., November 1. The dial-in number for
the telephone replay is 800-633-8284, ID #19851819.
AmeriPath is a leading national provider of cancer
diagnostics, genomics, and related information services.
The Company's extensive diagnostics infrastructure includes
425 pathologists and doctorate-level scientists, 42 independent
pathology laboratories, the Center for Advanced Diagnostics
(CAD), and Dermpath Diagnostics. CAD provides specialized
diagnostic testing and information services including
Fluorescence In-Situ Hybridization (FISH), Flow Cytometry,
DNA Analysis, Polymerase Chain Reaction (PCR), Molecular
Genetics, Cytogenetics, and HPV Typing. Dermpath Diagnostics,
with 68 board-certified dermatopathologists, is the country's
leading provider of dermatopathology services in the
growing skin diagnostic testing market. Additionally,
AmeriPath provides clinical trial and research and development
support to firms involved in developing new cancer and
genomic diagnostic and therapeutics.
.................................................................................................................
The statements contained
in this press release include "forward-looking
statements'' within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements
- which are sometimes identified by words such as "may", "should", "believe'', "expect'', "anticipate'', "estimate" and
similar expressions and which include any financial or
operating estimates, forecasts or projections - are subject
to a number of risks and uncertainties, many of which
involve factors or circumstances that are beyond the
Company's control. These risks and uncertainties could
cause actual results to differ materially from historical
results or from results anticipated by forward-looking
statements. These risks and uncertainties include: the
extent of success of the Company's operating initiatives
and growth strategies; ability to manage growth; access
to capital on satisfactory terms; general economic conditions;
a possible outbreak of hostilities or war; competition
and changes in competitive factors; federal and state
healthcare regulation (and compliance); reimbursement
rates under government and third party healthcare programs
and the payments received under such programs; changes
in coding; changes in technology; dependence upon pathologists
and customer contracts; the ability to attract, motivate,
and retain pathologists; labor and technology costs;
marketing and promotional efforts; the availability of
pathology practices in appropriate locations that the
Company is able to acquire on suitable terms or develop;
the successful completion and integration of acquisitions
(and achievement of planned or expected synergies); and
tax laws. The forward-looking statements in this press
release are made as of the date hereof based on management's
current beliefs and expectations, and the Company undertakes
no obligation to update or revise any such statements,
whether as result of new developments, new information
or otherwise. Further information regarding risks, uncertainties
and other factors that could affect the Company's financial
or operating results or that could cause actual results
to differ materially from those expected, estimated or
anticipated are included in the Company's annual, quarterly,
and other reports and filings with the SEC. Past performance
is not necessarily indicative of future results.
